928 related articles for article (PubMed ID: 10568115)
21. Use of heparin-bonded circuits in cardiopulmonary bypass improves clinical outcome.
Svenmarker S; Häggmark S; Jansson E; Lindholm R; Appelblad M; Sandström E; Aberg T
Scand Cardiovasc J; 2002 Aug; 36(4):241-6. PubMed ID: 12201973
[TBL] [Abstract][Full Text] [Related]
22. Clinical performance and biocompatibility of hyaluronan-based heparin-bonded extracorporeal circuits in different risk cohorts.
Gunaydin S; McCusker K; Sari T; Onur MA; Zorlutuna Y
Interact Cardiovasc Thorac Surg; 2010 Mar; 10(3):371-6. PubMed ID: 20026488
[TBL] [Abstract][Full Text] [Related]
23. Clinical study of platelet function and coagulation/fibrinolysis with Duraflo II heparin coated cardiopulmonary bypass equipment.
Nakajima T; Osawa S; Ogawa M; Sasaki T; Izumoto H; Yagi Y; Kawazoe K
ASAIO J; 1996; 42(4):301-5. PubMed ID: 8828788
[TBL] [Abstract][Full Text] [Related]
24. Biocompatibility of poly2methoxyethylacrylate coating for cardiopulmonary bypass.
Noguchi M; Eishi K; Tada S; Yamachika S; Hazama S; Izumi K; Tanigawa K
Ann Thorac Cardiovasc Surg; 2003 Feb; 9(1):22-8. PubMed ID: 12667126
[TBL] [Abstract][Full Text] [Related]
25. Comparable biocompatibility of Phisio- and Bioline-coated cardiopulmonary bypass circuits indicated by the inflammatory response.
Thiara AS; Andersen VY; Videm V; Mollnes TE; Svennevig K; Hoel TN; Fiane AE
Perfusion; 2010 Jan; 25(1):9-16. PubMed ID: 20172900
[TBL] [Abstract][Full Text] [Related]
26. Artificial surface-induced cytokine synthesis: effect of heparin coating and complement inhibition.
Lappegård KT; Fung M; Bergseth G; Riesenfeld J; Mollnes TE
Ann Thorac Surg; 2004 Jul; 78(1):38-44; discussion 44-5. PubMed ID: 15223398
[TBL] [Abstract][Full Text] [Related]
27. Effect of complement inhibition and heparin coating on artificial surface-induced leukocyte and platelet activation.
Lappegård KT; Fung M; Bergseth G; Riesenfeld J; Lambris JD; Videm V; Mollnes TE
Ann Thorac Surg; 2004 Mar; 77(3):932-41. PubMed ID: 14992902
[TBL] [Abstract][Full Text] [Related]
28. Clinical use of heparin-coated cardiopulmonary bypass in coronary artery bypass grafting.
Mirow N; Minami K; Kleikamp G; Tenderich G; Puhlmann T; Körfer R
Thorac Cardiovasc Surg; 2001 Jun; 49(3):131-6. PubMed ID: 11432470
[TBL] [Abstract][Full Text] [Related]
29. Blood activation during neonatal extracorporeal life support.
Plötz FB; van Oeveren W; Bartlett RH; Wildevuur CR
J Thorac Cardiovasc Surg; 1993 May; 105(5):823-32. PubMed ID: 7683735
[TBL] [Abstract][Full Text] [Related]
30. High and low heparin dose with heparin-coated cardiopulmonary bypass: activation of complement and granulocytes.
Ovrum E; Mollnes TE; Fosse E; Holen EA; Tangen G; Ringdal MA; Videm V
Ann Thorac Surg; 1995 Dec; 60(6):1755-61. PubMed ID: 8787476
[TBL] [Abstract][Full Text] [Related]
31. The effects of heparin and extracorporeal circulation on platelet counts and platelet microaggregation during cardiopulmonary bypass.
Muriithi EW; Belcher PR; Rao JN; Chaudhry MA; Nicol D; Wheatley DJ
J Thorac Cardiovasc Surg; 2000 Sep; 120(3):538-43. PubMed ID: 10962416
[TBL] [Abstract][Full Text] [Related]
32. Reducing the post-pump syndrome by using heparin-coated circuits, steroids, or aprotinin.
Harig F; Feyrer R; Mahmoud FO; Blum U; von der Emde J
Thorac Cardiovasc Surg; 1999 Apr; 47(2):111-8. PubMed ID: 10363611
[TBL] [Abstract][Full Text] [Related]
33. Descending thoracic aortic aneurysm repair with the aid of partial cardiopulmonary bypass: heparin-coated circuits versus nonheparin-coated circuits.
Morishita K; Kawaharada N; Fukada J; Hachiro Y; Kurimoto Y; Fujisawa Y; Saito T; Abe T
Artif Organs; 2005 Apr; 29(4):300-5. PubMed ID: 15787624
[TBL] [Abstract][Full Text] [Related]
34. Heparin-bonded cardiopulmonary bypass circuits reduce the rate of red blood cell transfusion during elective coronary artery bypass surgery.
Kreisler KR; Vance RA; Cruzzavala J; Mahnken JD
J Cardiothorac Vasc Anesth; 2005 Oct; 19(5):608-11. PubMed ID: 16202894
[TBL] [Abstract][Full Text] [Related]
35. Effects of methylprednisolone and a biocompatible copolymer circuit on blood activation during cardiopulmonary bypass.
Rubens FD; Nathan H; Labow R; Williams KS; Wozny D; Karsh J; Ruel M; Mesana T
Ann Thorac Surg; 2005 Feb; 79(2):655-65. PubMed ID: 15680854
[TBL] [Abstract][Full Text] [Related]
36. [The evaluation of the bio-compatibility and the clinical usefulness of heparin-coated cardiopulmonary bypass circuits].
Yamanaka J; Takeuchi Y; Torii S; Gomi A; Nakatani H; Kohno K
Nihon Kyobu Geka Gakkai Zasshi; 1996 Jan; 44(1):47-53. PubMed ID: 8683171
[TBL] [Abstract][Full Text] [Related]
37. Influence of Duraflo II heparin-treated extracorporeal circuits on the systemic inflammatory response in patients having coronary bypass.
Weerwind PW; Maessen JG; van Tits LJ; Stad RK; Fransen EJ; de Jong DS; Penn OC
J Thorac Cardiovasc Surg; 1995 Dec; 110(6):1633-41. PubMed ID: 8523873
[TBL] [Abstract][Full Text] [Related]
38. Does the additional use of heparin-coated extracorporeal circuits (ECC) optimize the effect of modified ultrafiltration (MUF) in pediatric perfusion?
Harig F; Meier C; Hakami L; Strasser R; Bretzger J; Münch F; Vestweber-Wilmes E; Singer H; Weyand M; Cesnjevar R
Thorac Cardiovasc Surg; 2006 Apr; 54(3):168-72. PubMed ID: 16639677
[TBL] [Abstract][Full Text] [Related]
39. Surface-bound heparin fails to reduce thrombin formation during clinical cardiopulmonary bypass.
Gorman RC; Ziats N; Rao AK; Gikakis N; Sun L; Khan MM; Stenach N; Sapatnekar S; Chouhan V; Gorman JH; Niewiarowski S; Colman RW; Anderson JM; Edmunds LH
J Thorac Cardiovasc Surg; 1996 Jan; 111(1):1-11; discussion 11-2. PubMed ID: 8551753
[TBL] [Abstract][Full Text] [Related]
40. Comparison of inflammatory responses after off-pump and on-pump coronary surgery using surface modifying additives circuit.
Quaniers JM; Leruth J; Albert A; Limet RR; Defraigne JO
Ann Thorac Surg; 2006 May; 81(5):1683-90. PubMed ID: 16631656
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
